Welcome to our dedicated page for SHUTTLE PHARMACTCLS HLDGS news (Ticker: SHPH), a resource for investors and traders seeking the latest updates and insights on SHUTTLE PHARMACTCLS HLDGS stock.
Shuttle Pharmaceuticals Holdings, Inc. develops cancer-therapy programs and drug-development technologies, with a focus on radiotherapy-related treatments and the Molecule.ai platform for molecular discovery and early-stage drug development. Its updates commonly address pipeline and platform development, including Ropidoxuridine, HDAC inhibitors, PSMA-B, PC-Rad Test and AI models for evaluating biological targets and therapeutic candidates.
Company news also includes financing activity, securities offerings, material agreements, shareholder-voting matters, governance updates and operating or financial results. The completed acquisition of Molecule.ai added an artificial-intelligence software asset to Shuttle Pharma's drug-discovery and predictive-analytics capabilities.
United Dogecoin, recently acquired by Shuttle Pharmaceutical Holdings (NASDAQ:SHPH), announced two key steps toward scaling Dogecoin mining operations. The company purchased its first fleet of ElphaPex DG1+ miners, each delivering 14.4 GH/s, and secured a hydroelectric data centre site providing renewable energy at US$0.064/kWh.
The miners are expected to be fully operational in about 60 days, subject to delivery and installation. United Dogecoin aims to leverage low-cost, renewable power as it pursues becoming the market’s largest Dogecoin miner by hashrate.
United Dogecoin, recently acquired by Shuttle Pharmaceutical Holdings (NASDAQ:SHPH), outlined a digital infrastructure strategy to support long-term DOGE mining and future AI hosting. The company is evaluating proprietary data centre and behind-the-meter power generation assets in Idaho and Alberta.
United Dogecoin is progressing toward electrification of its initial ElphaPex miners at a hosted facility, aiming to pair low-cost North American energy with owned power and data centre infrastructure to enhance operating flexibility and potential revenue from third-party high-performance computing and AI workloads.
Shuttle Pharma (NASDAQ:SHPH) approved a 10-for-1 reverse stock split of its common stock, effective June 11, 2026 at 12:01 a.m. Eastern Time.
SHPH will trade on a split-adjusted basis that day, with issued shares reduced from 6,371,075 to approximately 637,108. No fractional shares will be issued; amounts will be rounded up. The split also adjusts RSUs, warrants, pre-funded warrants and convertible preferred stock, uses new CUSIP 825693500, and is intended to support Nasdaq listing compliance and long-term capital structure.
Shuttle Pharmaceuticals (NASDAQ:SHPH) closed its merger with United Dogecoin, making United Dogecoin a wholly owned subsidiary. The combined company will focus on mining Dogecoin (DOGE) and Litecoin (LTC) and holding mined coins as long-term treasury assets.
Shuttle issued 8,000 shares of Series B-1 Convertible Preferred Stock, potentially convertible into about 32,264,000 common shares, reserved up to 118,038,551 pre-funded warrants tied to post-closing milestones, and completed a $9.55 million PIPE financing. A purchase order grants the option to buy up to 3,000 ElphaPex Scrypt mining rigs, expected to provide up to roughly 43,200 GH/s and begin coming online within 60 days of equipment receipt.
Shuttle (NASDAQ: SHPH) entered a definitive merger to acquire United Dogecoin and will issue Series B-1 preferred stock to United Dogecoin holders, subject to shareholder approval. A concurrent $11 million PIPE is expected to close May 4, 2026. United Dogecoin plans up to 3,000 ElphaPex rigs delivering up to 43,200 GH/s (~1.5% global Dogecoin hashrate) within 60 days and anticipates low-cost, renewable energy and preferential hardware access.
Shuttle (NASDAQ: SHPH) agreed to acquire United Dogecoin and will merge it into a wholly owned subsidiary, supported by an $11 million PIPE expected to close May 4, 2026. United Dogecoin intends to order up to 3,000 ElphaPex mining rigs for up to 43,200 GH/s (about 1.5% of global Dogecoin hashrate).
Transaction consideration includes 8,000 Series B-1 convertible preferred (≈32,258,064 common shares on conversion) and contingent pre-funded warrants tied to operational milestones; PIPE investors receive Series B-2 securities and warrants convertible upon shareholder approval.
Shuttle Pharmaceuticals (NASDAQ:SHPH) on March 27, 2026 announced a major upgrade to its molecule.ai platform, adding generative and predictive models plus a preview of an autonomous, multi-agent AI system for scientific workflows.
The release emphasizes multi-step reasoning, multimodal data ingestion, and orchestration to accelerate therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on March 26, 2026 announced a major expansion of its molecule.ai platform, adding new predictive and generative models and a preview of an autonomous, multi-agent AI system for scientific workflows.
The update enables multi-step reasoning, multimodal data ingestion, and prioritization of gene–disease and compound–target relationships to accelerate early therapeutic discovery and reduce manual research effort.
Shuttle Pharmaceuticals (NASDAQ: SHPH) announced a public offering to issue 2,238,800 shares of common stock and pre-funded warrants to purchase 4,761,200 shares for aggregate gross proceeds of approximately $3.5 million.
The offering is expected to close on or about March 9, 2026, with E.F. Hutton & Co. as exclusive placement agent. The company intends to use up to $1.5 million for marketing and the remainder for working capital and general corporate purposes. The securities are being offered under an effective Form S-1 (File No. 333-293363) registration statement.
Shuttle Pharmaceuticals (NASDAQ: SHPH) on January 13, 2026 highlighted Utah's new pilot allowing AI to authorize prescription refills and explained why that regulatory milestone matters for its Molecule.ai drug‑discovery platform. The release links Utah's AI refill program to time and cost savings in healthcare and argues Molecule.ai can similarly cut drug discovery bottlenecks by reducing time to identify candidates, lowering failed‑experiment costs, and automating repetitive screening.
The company says Molecule.ai uses agentic AI with uncertainty quantification, human‑in‑the‑loop workflows, and explainable models to enable oversight and scale while aiming to accelerate R&D and improve access to therapies.